This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of \[3H\]-semaglutide in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Subjects will receive a single dose subcutaneously (s.c., under the skin).
Novo Nordisk Investigational Site
Groningen, Netherlands
Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Total amount of [3H]-semaglutide related material excreted in urine (% of dose)
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Total amount of [3H]-semaglutide related material excreted in faeces (% of dose)
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Blood to plasma ratio of [3H]-semaglutide related material
Time frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide
Area under the semaglutide plasma concentration curve
Time frame: From time 0 until infinity after a single dose
Maximum observed semaglutide plasma concentration
Time frame: After a single dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.